New drugRepaglinide pharmacokinetics in healthy young adult and elderly subjects
References (14)
- et al.
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults
The pharmacological treatment of hyperglycemia in NIDDM
Diabetes Care
(1995)Non-insulin-dependent diabetes mellitus in the elderly
Bailliere's Clin Endocrinol Metab
(1997)Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus
Drugs Aging
(1997)Hypoglycemia and type II diabetes: Sulfonylureas
- et al.
Management of non-insulin-dependent diabetes mellitus in Europe: A consensus view
Diabetic Med
(1988) Physician's Guide to Non-Insulin-Dependent (Type II) Diabetes: Diagnosis and Treatment
(1988)
Cited by (57)
Hydrophilic interaction liquid chromatography–electrospray ionization mass spectrometry combined with fabric phase sorptive extraction for therapeutic drug monitoring of pioglitazone, repaglinide, and nateglinide in human plasma
2023, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesDevelopment and validation of RP-HPLC method for quantification of repaglinide in mPEG-PCL polymeric nanoparticles: QbD-driven optimization, force degradation study, and assessment of in vitro release mathematic modeling
2021, Microchemical JournalCitation Excerpt :Repaglinide is a conventional anti-diabetic drug approved by US-Food and Drug Administration (US-FDA) in 1998. It is rapidly absorbed from the gastrointestinal tract after oral administration and acts by inhibiting the ATP-sensitive potassium channel [3,4]. It differs from other anti-diabetic agents due to its structural activities, binding profile, duration of action, and mode of excretion.
Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp
2020, Biomedicine and PharmacotherapyCitation Excerpt :With this in mind, our study investigated the inhibitory influence of genistein on P-gp found that genistein enhanced the intestinal absorption of repaglinide in rats, showing the possibility of the combination use of repaglinide and genistein to treat diabetes. The pharmacokinetic characteristics of repaglinide in humans have been reported, indicating its rapid absorption and elimination with Tmax and T1/2 in an hour after oral administration [27–29]. It will be helpful to efficacy to find a nontoxic candidate for co-administration with repaglinide to improve its bioavailability.
Analysis of the variability of the pharmacokinetics of multiple drugs in young adult and elderly subjects and its implications for acceptable daily exposures and cleaning validation limits
2017, International Journal of Hygiene and Environmental HealthComparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study
2013, Current Therapeutic Research - Clinical and ExperimentalCitation Excerpt :During short- and long-term administration repaglinide has been well tolerated and few patients have withdrawn from treatment because of adverse effects.3,4 The pharmacokinetic profile of repaglinide has been reported in humans.5–7 Cmax is reached 30 to 60 minutes after administration.